Richard Bogan to Young Adult
This is a "connection" page, showing publications Richard Bogan has written about Young Adult.
Connection Strength
0.474
-
Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study. Lancet Neurol. 2022 01; 21(1):53-65.
Score: 0.088
-
Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy. Sleep. 2021 03 12; 44(3).
Score: 0.083
-
Effects of Solriamfetol on Quality-of-Life Measures from a 12-Week Phase 3 Randomized Controlled Trial. Ann Am Thorac Soc. 2020 08; 17(8):998-1007.
Score: 0.080
-
Demographic and nap-related variance of the MSLT: results from 2,498 suspected hypersomnia patients: Clinical MSLT variance. Sleep Med. 2019 03; 55:115-123.
Score: 0.072
-
Underutilization of the MSLT in sleepy patients with a short onset REM period (SOREMP) in the sleep clinic. Sleep Med. 2017 Apr; 32:150-156.
Score: 0.063
-
Weight loss in narcolepsy patients treated with sodium oxybate. Sleep Med. 2009 Jun; 10(6):661-3.
Score: 0.035
-
Longitudinal study of narcolepsy symptoms in first, second, and third-degree relatives of simplex and multiplex narcolepsy families. Sleep Med. 2019 01; 53:88-93.
Score: 0.017
-
The National Veteran Sleep Disorder Study: Descriptive Epidemiology and Secular Trends, 2000-2010. Sleep. 2016 Jul 01; 39(7):1399-410.
Score: 0.015
-
Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome. Mov Disord. 2011 Sep; 26(11):2065-72.
Score: 0.011
-
Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States. Mov Disord. 2010 Aug 15; 25(11):1675-83.
Score: 0.010